Literature DB >> 9754989

Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.

S Wanwimolruk1, S Bhawan, P F Coville, S C Chalcroft.   

Abstract

OBJECTIVE: Genetic oxidation polymorphisms of debrisoquine (CYP2D6) and proguanil (CYP2C19) were studied in unrelated healthy South Pacific Polynesian volunteers recruited in the South Island of New Zealand.
METHODS: Phenotyping for CYP2D6 and CYP2C19 activities was determined using debrisoquine and proguanil, respectively, as probe drugs by measuring the urinary metabolic ratio of parent drug and its metabolite.
RESULTS: Of 100 Polynesian subjects phenotyped, the metabolic ratio of debrisoquine ranged from 0.01 to 9.94. Therefore, all South Pacific Polynesians were classified as extensive metabolizers of debrisoquine according to previously established criteria of the antimode. The prevalence of poor metabolizers of debrisoquine (CYP2D6) in this Polynesian population is 0% (95% confidence interval of 0-3.6%). Oxidation polymorphism of CYP2C19 using proguanil as a probe was also studied in 59 Polynesian volunteers. The frequency distribution of the proguanil/cycloguanil ratio was bimodal. The proguanil/cycloguanil ratios for these subjects ranged from 0.09 to 34.4. Using a recommended proguanil/cycloguanil ratio cut-off point of 10 established in Caucasian populations, eight Polynesian subjects were identified as poor metabolizers of proguanil (CYP2C19), which corresponds to a poor metabolizer phenotype frequency of 13.6% (a 95% confidence interval of 5.9-24.6%).
CONCLUSION: The incidence of poor metabolizer phenotypes for debrisoquine (CYP2D6) in South Pacific Polynesians appears to lower than in Caucasian populations, while the prevalence of poor metabolizers for proguanil (CYP2C19) in this ethnic population is higher. The frequencies of the poor metabolizer phenotype for debrisoquine and also for proguanil in South Pacific Polynesians are similar to those reported in Asian populations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754989     DOI: 10.1007/s002280050488

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Dextromethorphan metabolic phenotyping in an Iranian population.

Authors:  Minoo Afshar; Mohammadreza Rouini; Shahram Ala
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract.

Authors:  Natasha P Clayton; Katsuhiko Yoshizawa; Grace E Kissling; Leo T Burka; Po-Chuen Chan; Abraham Nyska
Journal:  Exp Toxicol Pathol       Date:  2006-10-23

Review 4.  CYP2C19 and CYP2D6 genotypes in Pacific peoples.

Authors:  Nuala A Helsby
Journal:  Br J Clin Pharmacol       Date:  2016-08-26       Impact factor: 4.335

5.  Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.

Authors:  Mamta Behl; Abraham Nyska; Rajendra S Chhabra; Gregory S Travlos; Laurene M Fomby; Barney R Sparrow; Milton R Hejtmancik; Po C Chan
Journal:  Food Chem Toxicol       Date:  2011-08-18       Impact factor: 6.023

6.  The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.

Authors:  Khalifa Y Alrajeh; Youssef M Roman
Journal:  Per Med       Date:  2022-06-24       Impact factor: 2.119

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Toxicity of kava kava.

Authors:  Peter P Fu; Qingsu Xia; Lei Guo; Hongtao Yu; Po-Chuen Chan
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2008 Jan-Mar       Impact factor: 3.781

9.  A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea.

Authors:  Huai-Ling Hsu; Kathryn J Woad; D Graeme Woodfield; Nuala A Helsby
Journal:  Hum Genomics       Date:  2008-09       Impact factor: 4.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.